
Shares of vaccine maker Moderna MRNA.O rise 2.6% to $41.11 premarket
Co posts Q4 revenue of $678 million, beating LSEG-compiled analysts' average expectation of $626.1 million
Sales were primarily driven by Moderna's COVID-19 vaccine franchise
Reports a narrower quarterly loss of $2.11 per share from last year's loss of $2.91 per share
Up to last close, stock rose 36% YTD; MRNA fell 29% in 2025